Roivant Sciences Net Income/Loss 2021-2025 | ROIV

Roivant Sciences net income/loss for the twelve months ending March 31, 2025 was $-0.626B, a 108.17% decline year-over-year.

  • Roivant Sciences annual net income/loss for 2025 was $-0.357B, a 108.43% decline from 2024.
  • Roivant Sciences annual net income/loss for 2024 was $4.231B, a 479.32% decline from 2023.
  • Roivant Sciences annual net income/loss for 2023 was $-1.115B, a 20.71% increase from 2022.

Roivant Sciences Net Income/Loss 2021-2025 | ROIV

  • Roivant Sciences annual net income/loss for 2025 was $-0.357B, a 108.43% decline from 2024.
  • Roivant Sciences annual net income/loss for 2024 was $4.231B, a 479.32% decline from 2023.
  • Roivant Sciences annual net income/loss for 2023 was $-1.115B, a 20.71% increase from 2022.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.4B
Amgen (AMGN)$163.2B
Gilead Sciences (GILD)$142.1B
Vertex Pharmaceuticals (VRTX)$120.3B
Bristol Myers Squibb (BMY)$95.4B
CSL (CSLLY)$86B
GSK (GSK)$76.9B
Regeneron Pharmaceuticals (REGN)$60.3B
Alnylam Pharmaceuticals (ALNY)$43.1B
Argenex SE (ARGX)$36.6B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21B
Insmed (INSM)$19.9B
Biogen (BIIB)$18.7B
Illumina (ILMN)$17.2B
Incyte (INCY)$15B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14.5B
Moderna (MRNA)$12.6B
QIAGEN (QGEN)$11.4B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10B
Exelixis (EXEL)$9.9B
Bio-Techne Corp (TECH)$9.1B
Exact Sciences (EXAS)$9B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$7.5B
Halozyme Therapeutics (HALO)$7.3B